Abstracts tagged "observation and rheumatoid arthritis (RA)"

Abstract Number: 536 • 2018 ACR/ARHP Annual Meeting
Prevalence and Relative Factors for Frailty in Patients with RA from a Prospective Observational Study
Masahiro Tada¹, Yutaro Yamada², Koji Mandai³ and Noriaki Hidaka⁴, ¹Orthopaedic Surgery, Osaka City General Hospital, Osaka, Japan, ²Orthopedic surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ³Orthopaedic surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ⁴Orthopaedic surgery, Osaka City General Hospital, Osaka, Japan
Prevalence and relative factors for frailty in patients with RA from a prospective observational study Background/Purpose: Frailty is defined as degradation of physical and cognition…
Abstract Number: 2537 • 2018 ACR/ARHP Annual Meeting
Benefit Study: Results of Interim Analysis of a Pan-European Observational Study to Evaluate Real-World Effectiveness of SB4 Following Transition from Originator Etanercept (ETN) in Patients with Rheumatoid Arthritis (RA) or Axial Spondyloarthritis (AxSpA)
Klaus Krüger¹, Carlo Selmi^2,3, Alain Cantagrel⁴, Miguel A. Abad⁵, Ulrich Freudensprung⁶, Mourad Farouk Rezk⁶ and Janet Addison⁷, ¹Medical Centre of Rheumatology, Munich, Germany, ²Rheumatology and Clinical Immunology Unit, Humanitas Research Hospital, Rozzano (MI), Italy, ³BIOMETRA Department, University of Milan, Milan, Italy, ⁴Center of Rheumatology of CHU, Toulouse, France, ⁵FEA Reumatología, Hospital Virgen del Puerto, Cáceres, Spain, ⁶Biogen International GmbH, Zug, Switzerland, ⁷Biogen Idec, Maidenhead, United Kingdom
Background/Purpose: SB4, a biosimilar to the reference ETN, received EU marketing authorisation in January 2016, based on the totality of evidence from pre-clinical and clinical…
Abstract Number: 1039 • 2017 ACR/ARHP Annual Meeting
Influences for Therapeutic Changes in Rheumatoid Arthritis Patients from the Veterans Affairs Rheumatology Arthritis Registry Who Have Moderate to High Disease Activity
Brian Sauer¹, Jacob R. Stever¹, Chia-Chen Teng, MS¹, Neil Accortt², David Collier² and Grant Cannon¹, ¹Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ²Amgen Inc., Thousand Oaks, CA
Background/Purpose: Current guidelines encourage the measurement of rheumatoid arthritis (RA) disease activity to achieve a low disease state (treat-to-target). Many RA patients with documented moderate…
Abstract Number: 1364 • 2017 ACR/ARHP Annual Meeting
Incidence of Rheumatoid Arthritis in a Cohort of First Degree Relatives from the Studies of the Etiology of Rheumatoid Arthritis
Diraj R. Karnani¹, Lindsy J. Forbess², Michael Weisman³, Kevin D. Deane⁴, V. Michael Holers⁵ and Jill M. Norris⁶, ¹Department of Rheumatology, Cedars Sinai Medical Center, Los Angeles, CA, ²Medicine, Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ³Cedars-Sinai Medical Center Division of Rheumatology, Los Angeles, CA, ⁴Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ⁵Rheumatology Division, University of Colorado School of Medicine, Aurora, CO, ⁶Department of Epidemiology, Colorado School of Public Health, Aurora, CO
Background/Purpose: First-degree relatives (FDRs) of patients with rheumatoid arthritis (RA) are at increased risk for developing RA compared to the general population. The purpose of…
Abstract Number: 3197 • 2015 ACR/ARHP Annual Meeting
Clinical Practice Experience in Rheumatoid Arthritis Patients Treated with Triple Therapy and Methotrexate-Tumor Necrosis Factor Inhibition Differs from That of Randomized Controlled Trials
Daniel Erhardt¹, Brian Sauer², Chia-Chen Teng³, Ted R. Mikuls⁴, Jeffrey R. Curtis⁵, Derek Tang⁶, Bradley S. Stolshek⁶ and Grant W. Cannon¹, ¹Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ²Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ³HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Amgen, Inc., Thousand Oaks, CA
Background/Purpose: Recently published randomized controlled trials (RCTs) have demonstrated similar outcomes in rheumatoid arthritis (RA) patients treated with triple therapy [methotrexate (MTX), sulfasalazine (SUL) and…
Abstract Number: 584 • 2015 ACR/ARHP Annual Meeting
Positivity for Rheumatoid Factor Is Associated with a Better Short-Term Response and Long-Term Drug Retention of Abatacept: Results from Consecutive 508 Patients with Rheumatoid Arthritis in a Japanese Multicenter Registry
Nobunori Takahashi¹, Toshihisa Kojima¹, Koji Funahashi² and Naoki Ishiguro³, ¹Department of Orthopedic Surgery, Nagoya University Hospital, Nagoya, Japan, ²Nagoya University Hospital, Nagoya, Japan, ³Department of Orthopedic Suregery, Nagoya University Hospital, Nagoya, Japan
Background/Purpose: Abatacept (ABT) is a biologic drug and has been available for rheumatoid arthritis (RA) patients since 2010 in Japan. There have still been few…
Abstract Number: 130 • 2015 ACR/ARHP Annual Meeting
Disease Activity Patterns in Incident Onset Rheumatoid Arthritis Patients in the First 3-Years of Follow up
Mark Tatangelo¹, George A. Tomlinson², Bindee Kuriya³ and Claire Bombardier⁴, ¹University of Toronto, Toronto, ON, Canada, ²Medicine, Mount Sinai Hospital, Toronto, ON, Canada, ³Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁴Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada
Background/Purpose: Disease progression in longitudinal studies of rheumatoid arthritis (RA) is usually assessed by examining a measure of disease over time fixed time intervals. We…
Abstract Number: 42 • 2015 ACR/ARHP Annual Meeting
Does the Risk of Mortality in Patients with RA Change over Time or Disease Duration?
Kaleb Michaud^1,2, Sofia Pedro², Bryant R. England³ and Frederick Wolfe², ¹Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ²National Data Bank for Rheumatic Diseases, Wichita, KS, ³Division of Rheumatology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Observational studies have shown an increased risk of mortality in patients with RA, though none have done so with patients from all 50 US…
Abstract Number: 2414 • 2014 ACR/ARHP Annual Meeting
Etanercept in Mono Therapy or in Combination with MTX: Results from a Sub Analysis of a German Non-Interventional Study
Karl Heinz Goettl¹, Markus Gaubitz², Andreas Krause³, Udo Lendl⁴, Ralph Lippe⁴, Thomas Meng⁴ and Peter-Andreas Loeschmann⁵, ¹Joint practice for internal medicine, Passau, Germany, ²Academy of manual diagnostic at University of Münster, Münster, Germany, ³Konigstr. 63, Immanuel Krankenhaus Berlin, Berlin, Germany, ⁴Pfizer Pharma GmbH, Berlin, Germany, ⁵Loeschmann, Berlin, Germany
Background/Purpose Although a combination with MTX is recommended for all biologics, data from different registries around the world show that in real life around 30%…
Abstract Number: 480 • 2014 ACR/ARHP Annual Meeting
Serious Infection Risk By Treatments and Types in Patients with RA
Kaleb Michaud^1,2, Sofia Pedro¹, Andre Kalil³, Ted R. Mikuls⁴ and Frederick Wolfe¹, ¹National Data Bank for Rheumatic Diseases, Wichita, KS, ²Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ³Infectious Diseases, University of Nebraska Medical Center, Omaha, NE, ⁴University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Recent studies provide conflicting results on the impact of DMARDs on the risk of serious infections for patients with RA. We examined these infection…